In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukaemia

European Journal of Haematology

Volumn 58, Issue 5, 1997, Pages 301-306

  Morabito, F ^a   Callea, I ^a   Irrera, G ^a   Cartisano, G ^a   Dattola, A ^a   Rodino A ^a   Brugiatelli, M ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

6 methylprednisolone; Chlorambucil; CLL; Cytotoxicity; Deflazacort; MTT assay

Indexed keywords

CHLORAMBUCIL; DEFLAZACORT; METHYLPREDNISOLONE;

ARTICLE; B LYMPHOCYTE; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 0030840815     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb01675.x     Document Type: Article

References (36)

1. FAGUET G. Chronic lymphocytic leukemia: an updated review. J Clin Oncol 1994: 12: 1974-1990.
2. O'BRIEN S, DEL GIGLIO A, KEATING M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995: 85: 307-318.
3. ROZMAN C, MONTSERRAT E. Chronic lymphocytic leukemia. N Engl J Med 1995: 19: 1052-1057.
4. JAKSIC B, BRUGIATELLI M. High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL- IGCI CLL-01 trial. Nouv Rev Franc d' Hematol 1988: 30: 437-442.
5. JAKSIC B, BRUGIATELLI M, KRC I, et al. Comparison of high-dose chlorambucil versus Binet's modified chop regimen in B-cell chronic lymphocytic leukemia in advanced phase: results of an international multicentric randomized trial (abstract). Blood 1995: 86 (suppl 1): 607a.
6. BRUGIATELLI M, JAKSIC B, PLANINC-PERAICA A, et al. Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: long-term results of a randomized trial. Eur J Haematol 1995: 55: 158-163.
7. BOUNPAS DT, PALIOGIANNI F, ANASTASSIOU ED, BALOW JE. Glucocorticosteroid on the immune system: molecular and cellular aspects. Clin Exp Rheumatol 1991: 9: 413-423.
8. PALIOGIANNI F, RAPTIS S, AHUJA S, NAJJAR SM, BOUMPAS DT. Negative transcriptional regulation of human interleukin 2 (IL2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NFAT. J Clin Invest 1993: 91: 1481-1489.
9. CHENSUE SW, TERABUH PD, REMIC DG, SCALES WE, KUNKEL SL. In vivo biologic and immuno-histochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxinemia. Kinetics, Kupffer cell expression, and glucocorticoid effects. Am J Path 1991: 138: 395-402.
10. HICSONMEZ G, OZSOYLU S, TUNCER MA, ERTURK G, OZBEK N, KARADENIZ N. Direct morphological evidence of high-dose methylprednisolone induced maturation of leukemic cells in children with acute nonlymphoblastic leukemia. Exp Hematol 1991: 19: 241-246.
11. SMETS LA, VAN DEN BERG JD, ACTON D, TOP B, VAN ROOIJ H, VERWIJS-JANSSEN M. BCL-2 expression and mitochondrial activity in leukemic cells with different sensitivity to glucocorticoid-induced apoptosis. Blood 1994: 84: 1613-1619.
12. SMETS LA, VAN DEN BERG JD. Bcl-2 expression and glucocorticoid-induced apoptosis of leukemic and lymphoma cells. Leuk Lymph 1996: 20: 199-205.
13. BEGLEITER A, LEE K, ISRAELS LG, MOWAT MRA, JOHNSTON JB. Chlorambucil induced apoptosis in chronic lymphocytic leukemia (CLL) and its relationship to clinical efficacy. Leukemia 1994: 8 (suppl 1): 103-106.
14. O'BRIEN S, KANTARJAN H, BERAN M, et al. Results of Fludarabine and Prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993: 82: 1695-1704.
15. HAN T, EZDINLI EZ, SHIMAOKA K, DESAI DV. Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer 1973: 3: 502-508.
16. SPANISH COOPERATIVE GROUP PETHEMA. Treatment of chronic lymphocytic leukemia: a preliminary report of Spanish (Pethema) trials. Leuk Lymph 1991: 5 (suppl): 89-91.
17. CATOSKY D, RICHARDS S, FOOKS J, et al. CLL trials in the United Kingdom. The Medical Research Council CLL trials 1, 2 and 3. Leuk Lymph 1991: 5 (suppl): 105-111.
18. SCUDELLETTI M, CASTAGNETTA L, IMBIMBO B, PUPPO F, PIERRI I, INDIVERI F. New glucocorticoids mechanism of immunological activity at the cellular level and in the clinical setting. Ann NY Acad Sci 1990: 595: 368-382.
19. GENNARI G, IMBIMBO B, MONTAGNANI M, BERNINI M, NARDI P, AVIOLI V. Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calc Tissue Int 1984: 36: 245-252.
20. TRAPANI LOMBARDO V, MORABITO F, PUCCI G, et al. Treatment of idiopathic thrombocytopenic purpura with a new corticosteroid, deflazacort. Curr Ther Res 1991: 49: 1040-1045.
21. GOBBI M, SCUDELLETTI M. Deflazacort in the treatment of hematologic disorders. Eur J Clin Pharmacol 1993: 45 (suppl 1): 25-28.
22. MOSMANN T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Meth 1983: 65: 55-63.
23. HANSON JA, BENTLEY DP, BEAN EA, SARAH R, NUTE SR, MOORE JL. In vitro chemosensitivity testing in chronic lymphocytic leukaemia patients. Leuk Res 1991: 15: 565-569.
24. MORABITO F, MESSINA G, OLIVA B, et al. In vitro chemosensitivity of chronic lymphocytic leukemia B-cells to multidrug regimen (CEOP) compounds using the MTT colorimetric assay. Haematologica 1993: 78: 213-218.
25. SILBER R, DEGAR B, COSTIN D, et al. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood 1994: 84: 3440-3446.
26. MORABITO F, CALLEA I, RODINÒ A, et al. Modulation of purine analogs- and chlorambucil-induced cytotoxicity by alpha-interferon and interleukin-2 in chronic lymphocytic leukemia. Leukemia 1995: 9: 1425-1433.
27. MORABITO F, STELITANO C, CALLEA I. et al. In vitro chemosensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil : correlation with clinico-hematological and immunophenotypic features. Haematologica 1996: 81: 224-231.
28. CHESON BD, BENNETT JM, GREVER M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996: 87: 4990-4997.
29. VALERIOTE F, LIN HS. Synergistic interaction of anticancer agents: a cellular prospective. Cancer Chemother Rep 1975: 59: 895-899.
30. SONDAK OK, KORN EL, KERN DH. In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay. Int J Cell Cloning 1988: 6: 378-381.
31. BOSANQUET AG, BELL PB. Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined DiSC assay methodology. Leuk Res 1996: 20: 143-153.
32. NICOLETTI I, MIGLIORATI G, PAGLIACCI MC, GRIGNANI F, RICCARDI C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 1991; 139: 271-279.
33. KRAVTSOV V, LISHNER M, FABIAN I. A novel approach to study apoptosis in freshly isolated myeloblasts and chronic lymphocytic leukemia cells (abstract). Blood 1995: 86 (suppl 1): 837a.
34. JOHNSTON JB, VERBURG L, SHORE T, WILLIAMS M, ISRAELS LG, BEGLEITER A. Combination therapy with nucleoside analogs and alkilating. Leukemia 1994: 8 (suppl 1), 140-143.
35. ADAIR CG, BRIDGES JM, DESAI ZR. Can food affect the biovailability of chlorambucil in patients with haematological malignancies? Cancer Chemother Pharmacol 1986: 17: 99-102.
36. KASPERS GJL, VEERMAN AJP, PIETERS R, VAN ZANTWIJK I, HAHLEN K, VAN WERING ER. Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leuk Res 1995: 19: 175-181.